Initial US evaluation of secondgeneration capsule colonoscopy for detecting colon polyps

Douglas R. Morgan, Pramod R. Malik, David P. Romeo, Douglas Rex

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Capsule colonoscopy is an additional screening modality for colorectal cancer. Secondgeneration capsule colonoscopy (CC2) may have improved efficacy in the detection of colon adenomas as compared with prior devices. The purpose of this study was to evaluate the performance of CC2 in the detection of polyps in symptomatic and screening patients in the USA. Design: Prospective, multicentre study. Setting and participants: Two academic medical centres and two private practice facilities, evaluating patients with indications for colonoscopy. Methods: Patients underwent capsule colonoscopy procedure using magnesium citrate as a boost, followed by colonoscopy on the same day. The main outcome measurement was accuracy of CC2 for the detection of colorectal polyps ≥6 and ≥10 mm as compared with conventional colonoscopy. Results: 51 patients were enrolled, 50 of whom had CC2 and colonoscopy examinations and were included in the accuracy analysis. 30% and 14% of patients had polyps ≥6 and ≥10 mm, respectively. For lesions ≥10 mm identified on conventional colonoscopy, CC2 sensitivity was 100% (95% CI 56.1% to 100%) with a specificity of 93.0% (79.9% to 98.2%). For polyps ≥6 mm, the CC2 sensitivity was 93.3% (66.0% to 99.7%) and the specificity was 80.0% (62.5% to 90.9%). There was a 61% adequate cleansing rate with 64% of CC2 procedures being complete. Conclusions: In the initial US experience with CC2 there was adequate sensitivity for detecting patients with polyps ≥6 mm in size. Magnesium citrate was inadequate as a boost agent. Trial registration number: NCT01087528.

Original languageEnglish (US)
Article numbere000089
JournalBMJ Open Gastroenterology
Volume3
Issue number1
DOIs
StatePublished - Dec 31 2016

Fingerprint

Colonoscopy
Polyps
Capsules
Colon
Private Practice
Adenoma
Multicenter Studies
Colorectal Neoplasms
Prospective Studies
Equipment and Supplies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Initial US evaluation of secondgeneration capsule colonoscopy for detecting colon polyps. / Morgan, Douglas R.; Malik, Pramod R.; Romeo, David P.; Rex, Douglas.

In: BMJ Open Gastroenterology, Vol. 3, No. 1, e000089, 31.12.2016.

Research output: Contribution to journalArticle

Morgan, Douglas R. ; Malik, Pramod R. ; Romeo, David P. ; Rex, Douglas. / Initial US evaluation of secondgeneration capsule colonoscopy for detecting colon polyps. In: BMJ Open Gastroenterology. 2016 ; Vol. 3, No. 1.
@article{75cd4737aec141cc854c7100a577e7dd,
title = "Initial US evaluation of secondgeneration capsule colonoscopy for detecting colon polyps",
abstract = "Objectives: Capsule colonoscopy is an additional screening modality for colorectal cancer. Secondgeneration capsule colonoscopy (CC2) may have improved efficacy in the detection of colon adenomas as compared with prior devices. The purpose of this study was to evaluate the performance of CC2 in the detection of polyps in symptomatic and screening patients in the USA. Design: Prospective, multicentre study. Setting and participants: Two academic medical centres and two private practice facilities, evaluating patients with indications for colonoscopy. Methods: Patients underwent capsule colonoscopy procedure using magnesium citrate as a boost, followed by colonoscopy on the same day. The main outcome measurement was accuracy of CC2 for the detection of colorectal polyps ≥6 and ≥10 mm as compared with conventional colonoscopy. Results: 51 patients were enrolled, 50 of whom had CC2 and colonoscopy examinations and were included in the accuracy analysis. 30{\%} and 14{\%} of patients had polyps ≥6 and ≥10 mm, respectively. For lesions ≥10 mm identified on conventional colonoscopy, CC2 sensitivity was 100{\%} (95{\%} CI 56.1{\%} to 100{\%}) with a specificity of 93.0{\%} (79.9{\%} to 98.2{\%}). For polyps ≥6 mm, the CC2 sensitivity was 93.3{\%} (66.0{\%} to 99.7{\%}) and the specificity was 80.0{\%} (62.5{\%} to 90.9{\%}). There was a 61{\%} adequate cleansing rate with 64{\%} of CC2 procedures being complete. Conclusions: In the initial US experience with CC2 there was adequate sensitivity for detecting patients with polyps ≥6 mm in size. Magnesium citrate was inadequate as a boost agent. Trial registration number: NCT01087528.",
author = "Morgan, {Douglas R.} and Malik, {Pramod R.} and Romeo, {David P.} and Douglas Rex",
year = "2016",
month = "12",
day = "31",
doi = "10.1136/bmjgast-2016-000089",
language = "English (US)",
volume = "3",
journal = "BMJ Open Gastroenterology",
issn = "2054-4774",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Initial US evaluation of secondgeneration capsule colonoscopy for detecting colon polyps

AU - Morgan, Douglas R.

AU - Malik, Pramod R.

AU - Romeo, David P.

AU - Rex, Douglas

PY - 2016/12/31

Y1 - 2016/12/31

N2 - Objectives: Capsule colonoscopy is an additional screening modality for colorectal cancer. Secondgeneration capsule colonoscopy (CC2) may have improved efficacy in the detection of colon adenomas as compared with prior devices. The purpose of this study was to evaluate the performance of CC2 in the detection of polyps in symptomatic and screening patients in the USA. Design: Prospective, multicentre study. Setting and participants: Two academic medical centres and two private practice facilities, evaluating patients with indications for colonoscopy. Methods: Patients underwent capsule colonoscopy procedure using magnesium citrate as a boost, followed by colonoscopy on the same day. The main outcome measurement was accuracy of CC2 for the detection of colorectal polyps ≥6 and ≥10 mm as compared with conventional colonoscopy. Results: 51 patients were enrolled, 50 of whom had CC2 and colonoscopy examinations and were included in the accuracy analysis. 30% and 14% of patients had polyps ≥6 and ≥10 mm, respectively. For lesions ≥10 mm identified on conventional colonoscopy, CC2 sensitivity was 100% (95% CI 56.1% to 100%) with a specificity of 93.0% (79.9% to 98.2%). For polyps ≥6 mm, the CC2 sensitivity was 93.3% (66.0% to 99.7%) and the specificity was 80.0% (62.5% to 90.9%). There was a 61% adequate cleansing rate with 64% of CC2 procedures being complete. Conclusions: In the initial US experience with CC2 there was adequate sensitivity for detecting patients with polyps ≥6 mm in size. Magnesium citrate was inadequate as a boost agent. Trial registration number: NCT01087528.

AB - Objectives: Capsule colonoscopy is an additional screening modality for colorectal cancer. Secondgeneration capsule colonoscopy (CC2) may have improved efficacy in the detection of colon adenomas as compared with prior devices. The purpose of this study was to evaluate the performance of CC2 in the detection of polyps in symptomatic and screening patients in the USA. Design: Prospective, multicentre study. Setting and participants: Two academic medical centres and two private practice facilities, evaluating patients with indications for colonoscopy. Methods: Patients underwent capsule colonoscopy procedure using magnesium citrate as a boost, followed by colonoscopy on the same day. The main outcome measurement was accuracy of CC2 for the detection of colorectal polyps ≥6 and ≥10 mm as compared with conventional colonoscopy. Results: 51 patients were enrolled, 50 of whom had CC2 and colonoscopy examinations and were included in the accuracy analysis. 30% and 14% of patients had polyps ≥6 and ≥10 mm, respectively. For lesions ≥10 mm identified on conventional colonoscopy, CC2 sensitivity was 100% (95% CI 56.1% to 100%) with a specificity of 93.0% (79.9% to 98.2%). For polyps ≥6 mm, the CC2 sensitivity was 93.3% (66.0% to 99.7%) and the specificity was 80.0% (62.5% to 90.9%). There was a 61% adequate cleansing rate with 64% of CC2 procedures being complete. Conclusions: In the initial US experience with CC2 there was adequate sensitivity for detecting patients with polyps ≥6 mm in size. Magnesium citrate was inadequate as a boost agent. Trial registration number: NCT01087528.

UR - http://www.scopus.com/inward/record.url?scp=85043551862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043551862&partnerID=8YFLogxK

U2 - 10.1136/bmjgast-2016-000089

DO - 10.1136/bmjgast-2016-000089

M3 - Article

VL - 3

JO - BMJ Open Gastroenterology

JF - BMJ Open Gastroenterology

SN - 2054-4774

IS - 1

M1 - e000089

ER -